Reliability and validity of Chinese version of a tool to assess the quality of life in idiopathic pulmonary fibrosis in patients with interstitial lung disease

Rui-Li Pan a, Jeffrey J. Swigris b, Yan-Wei Zhao a, Ai-Min Guo c,*, Qing Wu c, Si-Jia Li c

a Department of Respiratory Medicine, Peking Union Medical College Hospital, Beijing, China
b Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, 1400, Jackson Street, Denver, CO, USA
c School of Nursing, Peking Union Medical College, Beijing, China

A B S T R A C T

Objective: This paper aims to determine the reliability and validity of the Chinese version of a tool that assesses the quality of life in idiopathic pulmonary fibrosis (cATAQ-IPF) in patients with interstitial lung disease (ILD).

Methods: We used the process of scale introduction to establish cATAQ-IPF. The content validity of the scale was evaluated by six experts. A total of 92 patients with ILD completed the cATAQ-IPF, St. George’s respiratory questionnaire (SGRQ), and The Medical Research Council dyspnoea scale at the baseline, and 15 patients completed cATAQ-IPF at the follow-up period 2 weeks later. Thus, yielding data were used to assess various psychometric properties of cATAQ-IPF. Intraclass correlation coefficient (ICC), Cronbach’s α coefficient, content validity index (CVI), item-level CVI (I-CVI), Pearson’s coefficients, criterion-relation validity, and known-group validity were used for data analysis.

Results: The cATAQ-IPF showed excellent test–retest reliability (ICC = 0.95), except for the therapy domain (Cronbach’s α = 0.60) and acceptable internal consistency (Cronbach’s α = 0.96 for the total). The scale-level CVI was 0.80, and the I-CVI was in the range of 0.78–1.00. The total cATAQ-IPF score was strongly correlated with the SGRQ total score (r = 0.71, P < 0.01). The cATAQ-IPF score of patients with ILD was 250.74 ± 47.39, and that of patients with IPF was 287.90 ± 22.56. Patients with IPF possessed considerable impairments in health-related quality of life according to the cATAQ-IPF score (t = 4.94, P < 0.01).

Conclusions: The cATAQ-IPF is a reliable and valid instrument for the evaluation of quality of life of Chinese patients with various forms of ILD.

© 2019 Chinese Nursing Association. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Interstitial lung diseases (ILDs), particularly idiopathic pulmonary fibrosis (IPF) that is one of the most common forms, are chronic, progressive conditions with remarkable morbidity and mortality. The median survival for IPF ranges from 3 years to 5 years, with half of mortality resulting from progressive respiratory failure [1,2]. Regardless of the cause, as ILD progresses, patients become severely limited in their activities and dependent on supplemental oxygen [3]. Fatigue, dyspnoea, and cough, which are disabling and impair health-related quality of life (HRQL) are the main symptoms of ILD [4]. Thus, health status and HRQL should be measured to assess the effect of disease and treatment efficacy [5].

Several instruments, such as St. George’s respiratory questionnaire (SGRQ) and The Medical Outcomes Short Form 36 (SF-36), have been used to measure HRQL in patients with ILD. However, instruments that have been developed specifically for patients with ILD are lacking. Therefore, developing a scale for patients with ILD...
to measure their HRQL is necessary. In 2010, Swigris [6] developed a questionnaire specifically to assess HRQL in patients with IPF. Questionnaire called a tool to assess quality of life in idiopathic pulmonary fibrosis (ATAQ-IPF) consists of 74 items comprising 13 domains and covers an extensive range of life quality. Although ATAQ-IPF was developed specifically for patients with IPF, it possesses face validity for all ILDs. To our knowledge, the reliability and validity of ATAQ-IPF in Chinese IPF population was demonstrated in 2013 but have not been administered to Chinese patients with ILD. This study aimed to introduce, administer, and test a Chinese version of ATAQ-IPF (cATAQ-IPF) in Chinese patients with ILD.

2. Methods

2.1. Study design

This work is an instrument translation and validation study. Access to the English version of ATAQ-IPF was granted by its developer (personal communication with Jeffrey J. Swigris). We used scale introduction methodology (translation, reverse translation, and culture adaptation) with input and oversight provided by Chinese ILD experts and Dr. Swigris to introduce cATAQ-IPF. cATAQ-IPF, SGRQ, and the Medical Research Council (MRC) dyspnoea scale were administered to the subjects, and analyses were conducted to assess the psychometric properties of cATAQ-IPF. This research was approved by the Institutional Review Board, and each participant provided a written informed consent [7,8].

2.2. Subjects

All patients with ILD evaluated at a tertiary hospital from January 2014 to August 2015 were considered for inclusion. ILD was diagnosed by integrating data on medical history, chest radiograph or high-resolution computed tomography scan, and transbronchial or surgical lung biopsy according to the published guidelines [9]. Patients with heart, liver, kidney, or mental diseases that precluded data collection or dominated their clinical picture were excluded. The final cohort included 92 subjects, 20 of which were diagnosed with IPF and 72 of which with other ILDs (non-IPF).

2.3. Cross-cultural adaptation

The cATAQ-IPF was produced using forward and back translations, with reconciliation by a panel of experts and cognitive interviewing in a small sample size of patients with ILD. The processes of translation and cross-cultural adaptation were performed in five stages, as follows: forward translation, translation synthesis, translation back to English, expert committee, and pretesting [10] (See Fig. 1).

2.4. Linguistic validation

In the medical review of the cATAQ-IPF, the plainest Chinese expressions were selected for every respondent to understand the questionnaire. Changes in the text of the cATAQ-IPF were unnecessary from the viewpoint of adaption to Chinese culture or translation to the Chinese language. In the pilot study, respondents understood the cATAQ-IPF without difficulty.

3. Measures

All questionnaires were completed using paper and pencil in a private room without assistance from a research personnel. The cATAQ-IPF, SGRQ, and MRC dyspnoea scale were completed at the baseline.

3.1. The cATAQ-IPF

The English version was developed by Swigris [6] and is composed of 74 items, comprising 13 domains, as follows: cough, dyspnoea, forethought, sleep, mortality, exhaustion, emotional well-being, social participation, finances, independence, sexual health, relationships, and therapies. All items used a five-point Likert response format from strongly disagree to strongly agree. The total score is in the range of 74–370, and high scores correspond to considerable impairment.

3.2. SGRQ

SGRQ is a respiratory-specific instrument developed for patients with COPD and widely used standardized assessment tool with three components, that is, symptoms, activity, and impacts. Scores for each component and a total score were calculated from the three components ranging from 0 to 100, with high scores indicating considerable disability [11]. Although designed for patients with obstructive disease, SGRQ is also a valid HRQL measurement tool for patients with restrictive lung disease [12].

3.3. MRC dyspnoea scale

The MRC dyspnoea scale has been in use for many years for grading the effect of breathlessness on daily activities. This scale measures perceived respiratory disability. It is consists of five statements on perceived breathlessness (scores are in the range of 1–5, with high scores indicating considerable dyspnoea). For the purposes of this study, scores of 1 or 2 were classified as mild, and scores of 3–5 were classified as moderate to severe.

4. Statistical analysis

4.1. Reliability

For test–retest reliability, a randomly selected group of 15 subjects completed the cATAQ-IPF at the baseline. At 2 weeks after completing the cATAQ-IPF, each patient confirmed a subjective stability in their disease prior to the completion of the cATAQ-IPF for the second time in an informal interview. This commonly used time interval was considered long enough for participants to avoid recalling and simply reiterating their baseline responses but also short enough to ensure that their clinical condition has remained stable. Test–retest reliability was examined using the intraclass correlation coefficient (ICC). The internal consistency reliability of the cATAQ-IPF was assessed using Cronbach’s α coefficient.

4.2. Validity

Content validity index (CVI) was assessed using scale- (S-CVI) and item-level CVI (I-CVI). To quantify CVI, experts should assess and quantize each item separately; note that each item should be scored between 1 and 4 (1, irrelevant; 2, unable to assess relevance without item revision or item is in need of such revision for it to be irrelevant; 3, relevant but needs minor revision; 4, very relevant and succinct). I-CVI is determined by the proportion of experts who gave a rating of 3 or 4 for every item, while S-CVI is determined by the proportion of all experts who gave a rating of 3 or 4 for all items [13,14].

Correlation between certain SGRQ and certain cATAQ-IPF scores was examined using Pearson’s coefficients. All statistical analyses were performed with SPSS version 18.0. Baseline data are presented as percentages or means with standard deviation as appropriate. We considered $P < 0.05$ to indicate statistical significance.
5. Results

5.1. Sample characteristics

A total of 92 surveys were administered. The overall response rate was 100%. The sample size was composed of 47.8% male ($n = 44$), and the average age was $55.80 \pm 11.78$ years. Most of the participants were diagnosed with ILD for $<3$ years. Nearly 40% of the participants had moderate to severe dyspnoea according to MRC dyspnoea scale (Table 1).

5.2. Reliability

Internal consistency and test–retest reliability results for the cATAQ-IPF are listed on Table 2. Internal consistency was 0.96 for the total score, with the dimensions in the range of 0.60–0.95. Only the therapy domain was lower than the acceptable 0.70 cut-off, and the 2-week test–retest reliability was 0.950 for the total score, with the dimensions in the range of 0.849–0.984. The corrected item-total correlations were in the range of 0.853–0.923. Ceiling or floor effects were nonexistent for the total cATAQ-IPF.

5.3. Validity

5.3.1. Content validity

The CVI of the cATAQ-IPF was evaluated by six medical experts.

Table 1

| Characteristics | Total patients ($n = 92$) | IPF ($n = 20$) | Non-IPF ($n = 72$) |
|-----------------|---------------------------|---------------|-------------------|
| Age, Mean ± SD  | 55.80 ± 11.78             | 58.25 ± 10.58 | 55.13 ± 12.07     |
| Gender          |                           |               |                   |
| Male            | 44 (47.8)                 | 14 (70.0)     | 30 (41.7)         |
| Female          | 48 (52.2)                 | 6 (30.0)      | 42 (58.3)         |
| Smoking status  |                           |               |                   |
| Smoked          | 30 (32.6)                 | 10 (50)       | 20 (27.2)         |
| Never           | 62 (67.4)                 | 10 (50)       | 52 (27.8)         |
| Disease course  |                           |               |                   |
| ≤3 years        | 74 (80.4)                 | 12 (60)       | 62 (86.1)         |
| >3 years        | 18 (19.6)                 | 8 (40)        | 10 (13.9)         |
| MRC grades      |                           |               |                   |
| 0               | 4 (4.3)                   | 0 (0)         | 4 (5.6)           |
| 1               | 21 (22.8)                 | 1 (5)         | 20 (27.6)         |
| 2               | 31 (33.7)                 | 7 (35)        | 24 (33.3)         |
| 3               | 23 (25.0)                 | 7 (35)        | 16 (22.2)         |
| 4               | 13 (14.1)                 | 5 (25)        | 8 (11.2)          |
| SGRQ score, Mean ± SD |                |               |                   |
| Symptoms        | 64.37 ± 26.89             | 80.25 ± 18.97 | 59.96 ± 27.20     |
| Activity        | 70.20 ± 24.50             | 85.45 ± 14.77 | 65.96 ± 25.04     |
| Impact          | 56.77 ± 24.59             | 74.85 ± 12.02 | 51.75 ± 24.87     |
| Total score     | 62.08 ± 21.75             | 78.65 ± 10.84 | 57.47 ± 21.81     |

The S-CVI was 0.80, and the I-CVI ranged from 0.78 to 1.00.

5.3.2. Criterion-relation validity

The criterion-relation validity of the cATAQ-IPF was acceptable. The correlation coefficient between the total cATAQ-IPF score and the total SGRQ score was 0.709 ($P < 0.01$). The score of the sexual health dimension was correlated insignificantly with any dimension of the total SGRQ score (Table 3).
5.3.3. Known-group validity

The cATAQ-IPF showed good known-group validity for IPF and non-IPF groups. The total scores of the cough, dyspnoea, forethought, sleep, exhaustion, emotional well-being, and relationship dimensions were significantly different in patients with and without IPF (P < 0.001; Table 4).

6. Discussion

For chronic, disabling illnesses, HRQL is an important outcome to examine when considering whether therapeutic interventions are beneficial. HRQL instruments can be generic or disease-specific. Although generic instruments can be applied in various clinical settings and also provide useful information for either ill or healthy populations by including items most relevant to patients with a particular disease, condition or disease-specific instruments are likely to be more sensitive than generic instruments to the changes in the status that result from therapeutic interventions.

In the present study, we translated the original ATAQ-IPF version, that is, the only IPF-specific HRQL instrument published to date, into Chinese and found that the cATAQ-IPF was a reliable and valid questionnaire useful in assessing HRQL in Chinese patients with various ILDs, not only IPF. We used linguistic validation to develop the cATAQ-IPF and confirmed that the instrument can be translated and adapted to Chinese patients.

Reliability is a generic term used to indicate both the homogeneity (internal consistency) of items composing a scale and the reproducibility (test–retest reliability) of a scale [15]. The ICC was 0.95, with values for the domains in the range of 0.85–0.98, thereby suggesting that cATAQ-IPF is a stable and reliable instrument in this population.

A cut-off of 0.70 is considered indicative of the acceptable internal consistency and test–retest reliability [16]. The internal consistency of 12 domains met this benchmark, except only for the therapy domain. Therapy domain showed low internal consistency reliability possibly due to the differences in insurance and medical treatment. All domain show significant statistically correlation except sexual health domain. It might be cultural differences between Eastern and Western countries that lead to this. In a study by Yunrong Liu [17], the main problem with administering surveys

| Table 2 | Reliability of the cATAQ-IPF in patients with ILD. |
|---------|--------------------------------------------------|
| Dimension | Cronbach's α | Total dimension | Corrected item-total correlation | Test–retest reliability (ICC) |
| 1. Cough | 0.95 | 0.63** | 0.853–0.923** | 0.946** |
| 2. Dyspnea | 0.88 | 0.78** | 0.752–0.835** | 0.937** |
| 3. Forethought | 0.92 | 0.73** | 0.839–0.892** | 0.941** |
| 4. Sleep | 0.88 | 0.65** | 0.480–0.597** | 0.912** |
| 5. Mortality | 0.85 | 0.60** | 0.420–0.879** | 0.935** |
| 6. Exhaustion | 0.80 | 0.82** | 0.468–0.868** | 0.935** |
| 7. Emotional well-being | 0.92 | 0.78** | 0.757–0.893** | 0.957** |
| 8. Social participation | 0.73 | 0.74** | 0.520–0.781** | 0.849** |
| 9. Finance | 0.81 | 0.66** | 0.200–0.914** | 0.982** |
| 10. Independence | 0.77 | 0.78** | 0.517–0.838** | 0.914** |
| 11. Sexual health | 0.84 | 0.24* | 0.464–0.828** | 0.914** |
| 12. Relationships | 0.72 | 0.61** | 0.248–0.790** | 0.984** |
| 13. Therapies | 0.60 | 0.61** | 0.267–0.714** | 0.887** |
| Total | 0.96 | 0.568** | 0.853–0.923** | 0.950** |

Note: **P < 0.01, *P < 0.05.

| Table 3 | Criterion-relation validity of the cATAQ-IPF. |
|---------|----------------------------------|
| Dimension | Symptoms | Activities | Impacts | Total SGRQ (r) | MRC (r) |
| 1. Cough | 0.356** | 0.170** | 0.523** | 0.516** | 0.609** |
| 2. Dyspnea | 0.405** | 0.539** | 0.675** | 0.670** | 0.645** |
| 3. Forethought | 0.408** | 0.574** | 0.611** | 0.645** | 0.645** |
| 4. Sleep | 0.192 | 0.367** | 0.421** | 0.412** | 0.412** |
| 5. Mortality | 0.205* | 0.377** | 0.431** | 0.429** | 0.429** |
| 6. Exhaustion | 0.325** | 0.490** | 0.653** | 0.619** | 0.619** |
| 7. Emotional well-being | 0.122 | 0.425** | 0.549** | 0.487** | 0.487** |
| 8. Social participation | 0.426** | 0.434** | 0.408** | 0.523** | 0.523** |
| 9. Finance | 0.274** | 0.258* | 0.366** | 0.354** | 0.354** |
| 10. Independence | 0.366** | 0.386** | 0.511** | 0.509** | 0.509** |
| 11. Sexual health | 0.044 | -0.014 | 0.092 | 0.052 | 0.052 |
| 12. Relationships | 0.553** | 0.317** | 0.330** | 0.417** | 0.417** |
| 13. Therapies | 0.218* | 0.329** | 0.490** | 0.444** | 0.444** |
| cATAQ-IPF | 0.440** | 0.568** | 0.719** | 0.709** | 0.555** |

Note: **P < 0.01, *P < 0.05.

| Table 4 | Comparison of quality of life in patients with different diseases. |
|---------|----------------------------------|
| Dimension | IPF (n = 20) | Non-IPF (n = 72) | t value | P-value |
| Total score | 287.90 ± 22.56 | 250.74 ± 47.39 | 4.938 | <0.001 |
| 1. Cough | 24.70 ± 4.66 | 17.58 ± 7.80 | 5.122 | <0.001 |
| 2. Dyspnea | 26.60 ± 3.95 | 21.76 ± 6.11 | 3.342 | 0.001 |
| 3. Forethought | 22.25 ± 3.40 | 19.61 ± 5.24 | 2.126 | 0.036 |
| 4. Sleep | 23.15 ± 4.63 | 19.67 ± 6.80 | 2.662 | 0.011 |
| 5. Mortality | 20.90 ± 4.77 | 18.41 ± 5.71 | 1.769 | 0.080 |
| 6. Exhaustion | 21.30 ± 2.32 | 16.71 ± 4.86 | 5.943 | <0.001 |
| 7. Emotional well-being | 27.55 ± 4.37 | 24.90 ± 7.39 | 2.023 | 0.048 |
| 8. Social participation | 22.10 ± 2.22 | 20.39 ± 3.90 | 1.875 | 0.064 |
| 9. Finance | 23.30 ± 3.95 | 22.57 ± 5.22 | 0.581 | 0.563 |
| 10. Independence | 20.60 ± 3.71 | 18.88 ± 4.16 | 1.679 | 0.097 |
| 11. Sexual health | 18.15 ± 3.82 | 16.68 ± 3.01 | 1.818 | 0.072 |
| 12. Relationships | 19.00 ± 2.71 | 16.04 ± 4.04 | 3.518 | 0.001 |
| 13. Therapies | 18.30 ± 4.00 | 17.51 ± 4.17 | 0.753 | 0.454 |

Note: *P-values from Student's t-tests or correlations as appropriate.
regarding sex to Chinese people was that the respondents outright refuse to respond to these items or are unable to answer questions truthfully.

Incorporating the opinions from a committee of experts increases confidence that the cATAQ-IPF covers topics and domains relevant to Chinese patients with ILD. Among CVIs, the most widely used are the CVIs introduced by Hambleton and Martuzza [18]; these CVIs include I-CVI and S-CVI, which are used to assess the content validity of each item and the whole scale, respectively. Some studies have shown that when the number of experts is ≥ 6, the I-CVI should be ≥ 0.78 [14]. Davis [15] recommended in his study that the S-CVI should be ≥ 0.8. In the present study, six experts were consulted. The I-CVI ranged from 0.78 to 1.00, and a S-CVI of >0.8 indicated good content validity.

SGRQ was chosen as a criterion variable. Although it was developed for patients with obstructive lung diseases, SGRQ has frequently been used to measure HRQL in patients with IPF and other ILDs [19–22]. Significant correlations in the expected direction between the cATAQ-IPF and SGRQ scores supported the criterion validity of the cATAQ-IPF, while only the moderate strength of those correlations confirmed that each issue provided unique information. A medium correlation between cATAQ-IPF and SGRQ was attributed to the fact that SGRQ mainly described dyspnoea, while ATAQ-IPF possessed 13 dimensions, that making a comprehensive review on the quality of life of patients with ILD.

7. Problems in the scale usage

cATAQ-IPF composed many items, thereby requiring 40 min to complete. However, the advantage of using a multidimensional questionnaire, that is, one that captures all domains relevant to a patient group (e.g., cATAQ-IPF), was that other questionnaires were unnecessary. For instance, a dyspnoea scale was unnecessary because the cATAQ-IPF contains one that was relevant to this disease. A cough questionnaire was unnecessary because the cATAQ-IPF includes a cough scale. Considering cultural differences, although items were translated well, some of these items were inapplicable to Chinese patients (e.g., item 42: “I limit the amount that I travel because I have IPF.”). Most of the subjects were hospitalized; thus, their responses may not reflect Chinese patients with ILD in general. The limitation of this study included the lack of factor analysis for retesting the subscale structure and cultural differences. Factor analysis can be added in the future study. The number of cases in this study was limited because it was difficult to collect. Contrasted-group and known-group validity should be added in the future study. The cATAQ-IPF needs to be revised on the cross-cultural adaptation of self-report measures. Spine 2000;25(24): 3186–91.

Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health-status for chronic air-flow limitation - the st-georges respiratory questionnaire. Am Rev Respir Dis 1992;145(6): 1231–7.

De Vries J, Drent M. Quality of life and health status in interstitial lung diseases. Curr Opin Pulm Med 2006;12(5): 354–8.

Mary L. Determination and qualification of content validity. Nurs Res 1985; 382–5.

Davis LL. Instrument review Getting themost from your panel of experts. Clin Res Methodol 1992:194–6.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jjins.2018.11.005.

References

[1] Tukiainen P, Taskinen E, Holsti P, Korholta O, Valle M. Prognosis of cryptogenic fibrosing alveolitis. Thorax 1983;38(5): 349–55.
[2] Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis - a population-based cohort study. Chest 1998;113(2): 396–400.
[3] Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of health-related quality of life in patients with interstitial lung disease. Chest 1999;116(5): 1175–82.
[4] Madison JM, Irwin RS. Chronic cough in adults with interstitial lung disease. Curr Opin Pulm Med 2005;11(5): 412–6.
[5] Yorke J, Swigris J, Russell AM, Moosavi SH, Kwong GNM, Longshaw M. Jones PW, Dyspnoea-12 is a valid and reliable measure of breathlessness in patients with interstitial lung disease. Chest 2011;139(1): 59–64.
[6] Swigris JJ, Wilson SR, Green KE, Springer DB, Brown KK, Wamboldt FS. Development of the ATAQ-IPF: a tool to assess quality of life in IPF. Health Qual Life Outcome 2010;8:77.
[7] Blanchette MA, Normand MC. Cross-cultural adaptation of the patient-rated tennis elbow evaluation to Canadian French. J Hand Ther 2010;23(3): 290–9.
[8] Gjersing L, Caplehorn JR, Clausen T. Cross-cultural adaptation of research instruments: language, setting, time and statistical considerations. BMC Med Res Methodol 2010;10:13.
[9] Raghu G, Collard HR, Egan JJ, Martinez FJ. An official ATS/ERS/EBL/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183(6): 788–824.
[10] Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine 2000;25(24): 3186–91.
[11] Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health-status for chronic air-flow limitation - the st-georges respiratory questionnaire. Am Rev Respir Dis 1992;145(6): 1231–7.
[12] De Vries J, Drent M. Quality of life and health status in interstitial lung diseases. Curr Opin Pulm Med 2006;12(5): 354–8.
[13] Mary L. Determination and qualification of content validity. Nurs Res 1985; 382–5.
[14] Davis LL. Instrument review Getting themost from your panel of experts. Clin Res Methodol 1992:194–6.
[15] Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health-status measures - statistics and strategies for evaluation. Contr Clin Trials 1991;12(4): 514–58.
[16] Lee J. coefficient_alpha and the internal surracte of tests. Psychometrika 1935;16(3): 297–334.
[17] Yunrong L, Yongjie C. Quality of sexual life and related factors for Chinese married women of childbearing age. Chin J Fam Plan 2002;2: 98–101.
[18] Hambleton RK, Swanimanathan H, Alina J, Billcoulson D. criterion-referenced testing and measurement a review of technical issues and developments. Rev Educ Res 1978;48(1): 1–47.
[19] Swigris JJ, Esser D, Consolendo CS, Brown KK. The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcome 2014;12: 124.
[20] Yorke J, Jones PW, Swigris JJ. Development and validity testing of an IPF-specific version of the St george's respiratory questionnaire. Thorax 2010;65(10): 921–6.
[21] Jeffrey J, Swigris DMS, Kevin K, Brown M, Juergen Behr M, Bois RMD, Talmadge E, King JR, Ganesh Raghu M, Frederick S, Wamboldt M. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010;104(2): 296–304.
[22] Jeffrey J, Swigris DM, Hye-Seung Lee P, Marsha Cohen M, St. George's respiratory questionnaire has longitudinal construct validity in lymphangioleio- myomatosis. Chest 2013;143(6): 1671–8.